MAPT and myeloid sarcoma: It was previously determined that Amyloid PET using Florbetapir (18F) provided a sensitivity and specificity of over 92%.82 Evaluations of Aβ and tau biomarkers in patients with MS tend to show decreased deposition of Aβ with no significant change in tau accumulation.